KIRKLAND, QC, June 30, 2016 /CNW Telbec/ - Ortho Regenerative Technologies Inc. ("Ortho RTI" or the "Corporation"), a Canadian orthopaedic biotechnology company, announces that it has granted an aggregate 371,800 share options on June 23, 2016 in connection with agreements ("Agreements") entered into with one executive and three consultants of the Corporation, each such share option entitling the holders thereof to acquire one Class "A" Share of Ortho RTI at an exercise price of $0.50 for a period of five years. The options will vest pursuant to share options agreements between Ortho RTI and each optionee.
Appointment of new Chief Financial Officer
Ortho RTI is also pleased to announce the appointment of Jo-Anne Mainguy-Piché as Chief Financial Officer of the Corporation, effective June 23, 2016. Helen Saviuk who held the CFO position until then will continue in her current capacity as Chief Financial Officer of Manitex Capital Inc. and Valeo Pharma Inc., both being affiliates of Ortho RTI.
Ms. Mainguy-Piché holds a Bachelor in Accounting from Université du Québec à Montréal and is a CPA Auditor, CGA with over 25 years experience in accounting, working with both private and public companies. Ms. Mainguy-Piché has held Senior Manager positions with two national accounting firms as well as senior executive positions with private companies in various sectors. In the course of her career, Ms. Mainguy-Piché assisted a number of companies with successfully planning and executing significant corporate milestones such as IPOs, reverse take-overs, mergers and acquisitions, as well as strategic planning.
Caution regarding forward-looking statements
This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.
About Ortho Regenerative Technologies Inc.
Ortho RTi is a Canadian orthopaedic biotechnology company dedicated to the development of medical devices that treat unmet needs in the orthopaedic market. Based on a proprietary biopolymer platform, the company is developing new regenerative treatments for soft tissue tears in the shoulder and knee as well as articular cartilage injuries, all currently with few productive options for repair.
SOURCE Ortho RTI
For further information: Steve Saviuk, Executive Chairman, Ortho RTi, saviuk@OrthoRTi.com, 514-782-0951